Selective GAT-1 inhibitors such as tiagabine have anxiolytic and antidepressant effects in mice [56], and novel GAT-1 inhibitors are now being tested as potential treatments for anxiety and depression [57]. Here, SLC6A1 is linked to depressive symptom measurement.